胰腺管道腺癌细胞调节NLRP3激活,产生一个宽容的微环境
Jesus Amo-Aparicio1, Adrian Dominguez2, Shaikh M Atif1
1Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Cancer research communications
|September 29, 2023
概括
胰腺癌细胞激活NLRP3炎症酶,抑制抗瘤免疫力. 抑制NLRP3可以恢复CD8+T细胞的功能,提高抗胰腺管道腺癌 (PDAC) 的化疗疗效率.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 胰腺管道腺癌 (PDAC) 具有免疫耐受性微环境的特征,有助于高死亡率和耐药性.
- PDAC细胞释放CSF-1,激活骨髓细胞中的NLRP3炎症酶,PDAC患者的NLRP3炎症酶升高.
研究的目的:
- 阐明PDAC细胞通过NLRP3炎症酶激活促进免疫耐受性的机制.
- 研究在PDAC中准NLRP3的治疗潜力.
主要方法:
- 利用了人类的原始细胞和一个正极形的PDAC小鼠模型.
- 评估了NLRP3表达,炎症酶形成,IL1β成熟和Th1/Th2免疫反应.
- 研究了基因删除和NLRP3的药理抑制对瘤生长和CD8+T细胞激活的影响.
- 评估了NLRP3抑制剂与凝胺的联合治疗.
主要成果:
- 激活NLRP3驱动IL1β成熟和Th2型炎症通过COX2 / PGE2,抑制CD8 + T细胞反应并促进瘤扩张.
- 抑制NLRP3逆转了Th2倾斜,促进了Th1免疫力,增加了IL2水平,并调解了CD8+T细胞瘤抑制.
- 药理上抑制NLRP3,特别是与凝胺联合使用时,显著增强了抗瘤功效.
结论:
- 瘤介导的NLRP3激活通过操纵适应性免疫来促进免疫逃避和PDAC的进展.
- 准NLRP3是一个有希望的治疗策略,可以克服免疫耐受性并改善PDAC的治疗结果.
- 口服NLRP3抑制剂,如OLT1177,提供一种转化方法来提高化疗疗效.
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K